Makena: Professional Societies Finally See Eye To Eye With US FDA’s Drugs Center
Executive Summary
After two decades of recommending use of intramuscular 17-OHPC to prevent preterm birth, the American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine revised their clinical guidelines in the wake of the FDA’s order withdrawing Covis’ Makena and its generics.
You may also be interested in...
Preterm Birth Patients Sought By US FDA As Meeting On Treatment Development Looms
With the only FDA-approved treatment off the market, the FDA is looking for ideas for development of new preterm birth treatments.
Increased Cancer Risk & Effectiveness Concerns Prompt EU-Wide Review Of Preterm Birth Medicine
The European Medicines Agency is re-examining the benefits and risks of hydroxyprogesterone medicines for gynecologic and obstetrical conditions at the request of the French regulator ANSM.
Accelerated Approval: US FDA, Covis Navigate Novel Issues With Makena’s Withdrawal
Ahead of the final withdrawal decision, FDA terminated internal separation of functions so that the Office of the Commissioner and CDER could coordinate next steps; Makena’s NDA approval has been withdrawn, but the product’s website lives on, albeit with a pop-up window explaining the regulatory action.